The estimated Net Worth of Margaret Koziel is at least $118 millier dollars as of 1 March 2023. Dr Koziel owns over 679 units of Axcella Health Inc stock worth over $113,964 and over the last 3 years he sold AXLA stock worth over $3,987.
Dr has made over 4 trades of the Axcella Health Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 679 units of AXLA stock worth $394 on 1 March 2023.
The largest trade he's ever made was selling 679 units of Axcella Health Inc stock on 1 March 2023 worth over $394. On average, Dr trades about 296 units every 46 days since 2021. As of 1 March 2023 he still owns at least 24,883 units of Axcella Health Inc stock.
You can see the complete history of Dr Koziel stock trades at the bottom of the page.
Dr. Margaret Koziel M.D. is the Sr. VP & Chief Medical Officer at Axcella Health Inc.
Margaret's mailing address filed with the SEC is 1350 OLD BAYSHORE HIGHWAY, SUITE 400, , BURLINGAME, CA, 94010.
Over the last 5 years, insiders at Axcella Health Inc have traded over $32,393 worth of Axcella Health Inc stock and bought 29,966,648 units worth $79,278,835 . The most active insiders traders include Ventures Fund Iv General Pa..., Ventures Fund Iv General Pa... et Des Produits Nestle S.A.Nes.... On average, Axcella Health Inc executives and independent directors trade stock every 31 days with the average trade being worth of $3,073,698. The most recent stock trade was executed by Margaret Koziel on 1 March 2023, trading 679 units of AXLA stock currently worth $394.
axcella has pioneered a new therapeutic class – defined amino acid compositions (daacs™). our daac therapeutics leverage the essential signaling function of amino acids to restore health across a network of dysregulated pathways, and provide safer solutions for patients with complex disease. with our axcellerator™ platform, we are transforming traditional drug discovery and development by generating patient data in less than a year from indication selection. this platform has delivered a rich pipeline including clinical programs in liver, metabolic, cns and orphan diseases.
Axcella Health Inc executives and other stock owners filed with the SEC include: